Review Article

The Role of BPIFA1 in Upper Airway Microbial Infections and Correlated Diseases

Yung-An Tsou,1,2 Min-Che Tung,3,4 Katherine A. Alexander,5 Wen-Dien Chang6,6, Ming-Hsui Tsai,1 Hsiao-Ling Chen,7 and Chuan-Mu Chen1,2,8

1Department of Otolaryngology Head and Neck Surgery, School of Medicine, China Medical University Hospital, Taichung 404, Taiwan
2Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan
3Department of Surgery, Tungs’ Taichung MetroHarbor Hospital, Taichung 435, Taiwan
4Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei 110, Taiwan
5Department of Biology, Washington University in St. Louis, St. Louis, Missouri 63130, USA
6Department of Sport Performance, National Taiwan University of Sport, Taichung 404, Taiwan
7Department of Bioresources, Da-Yeh University, Changhua 515, Taiwan
8The iEgg and Animal Biotechnology Center, and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan

Correspondence should be addressed to Chuan-Mu Chen; chchen1@dragon.nchu.edu.tw

Received 9 April 2018; Revised 4 July 2018; Accepted 7 August 2018; Published 3 September 2018

Academic Editor: Mariagrazia Di Luca

Copyright © 2018 Yung-An Tsou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The mucosa is part of the first line of immune defense against pathogen exposure in humans and prevents viral and bacterial infection of the soft palate, lungs, uvula, and nasal cavity that comprise the ear-nose-throat (ENT) region. Bactericidal/permeability-increasing fold containing family A, member 1 (BPIFA1) is a secretory protein found in human upper aerodigestive tract mucosa. This innate material is secreted in mucosal fluid or found in submucosal tissue in the human soft palate, lung, uvula, and nasal cavity. BPIFA1 is a critical component of the innate immune response that prevents upper airway diseases. This review will provide a brief introduction of the roles of BPIFA1 in the upper airway (with a focus on the nasal cavity, sinus, and middle ear), specifically its history, identification, distribution in various human tissues, function, and diagnostic value in various upper airway infectious diseases.

1. Introduction

The gene of the short palate, lung, and nasal epithelium clone 1 (splunc1), now referred to as BPIFA1, was first described in the palate and nasal epithelium of murine embryonic and adult lung tissue, which is referred to as plunk [1]. The human gene that encodes BPIFA1 contains nine exons that are located on chromosome 20q11.2, and its expression is limited to the upper airway and nasopharyngeal region, including the trachea and nasal epithelium [2, 3]. Di and his colleagues [4] determined that this gene, referred to as spurt (secretory protein in upper respiratory tract), was significantly induced by all-trans-retinoic acid in primary cultured human tracheobronchial epithelia.

BPIFA1 is a member of a family of seven proteins that are encoded by adjacent genes in an approximately 300 kb region of chromosome 20q11 (Figure 1). The human BPIFA1 cDNA is 1,020 bp in length and contains a leucine-rich protein of 256 amino acids weighing approximately 25 kDa [2]. BPIFA1 is also a member of the parotid secretory protein (PSP)/lipopolysaccharide-binding protein (LBP) superfamily of proteins [5]. Members of the PLUNC family fall into two groups based on their size: "short" proteins, a group comprising BPIFA1 (256 amino acids), SPLUNC2 (249 amino acids) and SPLUNC3 (253 amino acids) and "long" proteins comprising LPLUNC1 (484 amino acids), LPLUNC2 (458 amino acids), LPLUNC3 (463 amino acids), and LPLUNC4 (>469 amino acids) [6]. LPLUNC6/BPIFB6 is important in
some virus replication as coxsackievirus B (CVB), poliovirus (PV), and enterovirus 71 (EV71) [7].

SPLUNC proteins contain domains structurally similar to the N-terminal domain of bactericidal/permeability-increasing protein (BPI), whereas LPLUNC proteins contain domains structurally similar to both domains of BPI [6, 8].

Human BPIFA1 is expressed in the salivary gland, and nose of the upper respiratory tract [21]. High expression of BPIFA1 is also found in normal adult nasopharyngeal epithelium [2, 6, 22], trachea, bronchi of the adult lung [1, 23]. Various reports have demonstrated that bactericidal/permeability-increasing fold containing family A, member 1 (BPIFA1) is present in the innate immune material that protects against various diseases and has been widely reported in humans to play a role in lower airway defense against different kinds of bacterial infection. For example, higher levels of BPIFA1 have been correlated with the presence of Pseudomonas pneumonia [16, 24, 25], Klebsiella pneumonia [26], Mycoplasma pneumonia [27], and Staphylococcus aureus [28]. BPIFA1 also plays an important role in the innate immunity of the pulmonary airway against influenza A [20, 29] and respiratory syncytial virus infection [14]. Other lower respiratory tract diseases, notably cystic fibrosis, have also demonstrated a correlation between BPIFA1 expression and disease progression [21, 30]. Several reports illustrated a correlation between BPIFA1 expression and middle ear infection [31], chronic rhinosinusitis with nasal polyps (CRSwNP) [32, 33], and sinusitis [34]. Quantitation of BPIFA1 expression could be applied as a diagnostic tool for certain upper airway diseases and may have a value for determining treatment outcomes. Although existing reviews have examined the functions of BPIFA1 and correlations with lower airway diseases, few studies have focused on its functions and correlates in the upper airway.

2. BPIFA1 Expression and Regulation

After searching the databases, the BPIFA1 in various upper airway infectious diseases was retrieved. Overall, BPIFA1 has been examined through specific expression in upper airway tracts, including the tongue, tonsil, nasal polyps, adenoid, and middle ear (Figure 2). The materials that affect BPIFA1 expression were summarized to assess future therapeutic applications of this secretory protein in treating upper airway-related diseases (Table 1). Although there are currently no regimens for direct supplementation with BPIFA1, repression of BPIFA1 in patients may still be prevented by controlling or treating the patient’s underlying allergic rhinitis or asthma-related disease. This approach may decrease levels of IL-13, a cytokine
Table 1: Materials that affect BPIFA1 expression.

| Effector of BPIFA1 expression | Study design materials | Correlated diseases | Disease findings | Mechanism/pathway | Biofilm correlation/pathogen |
|------------------------------|------------------------|---------------------|------------------|-------------------|---------------------------|
| IL-13                        | Human nasal lavage fluid | Allergic rhinitis | Lower in allergy | ERK               | Not mentioned/not mentioned |
|                              | Tissue specimens by sinus surgery | LPS treated RPMI-2650 | Lower in polyps tissue | JNK, AP1 | Not mentioned/LPS toxin |
| Lactoferrin                  | RPMI-2650 cells         | Recovery of BPIFA1 | Inhibition of MEK/ERK pathway | Not mentioned/LPS toxin |
| Intrasal steroid             | RPMI-2650 cells         | Recovery of BPIFA1 | Reactivation of AP-1 | Not mentioned/LPS toxin |
| MMP9 (matrix metallo-proteinase 9) | Targets cells/macrophages/oral epithelia/airway epithelia | PLUNC inhibited by MMP9 | PLUNC protein proteolytically cleaved by MMP9 | Not mentioned/microorganisms colonization |

Secreted by many cell types, primarily Th2 helper T cells, to help mediate anti-inflammatory responses to allergens and prevent downregulation of BPIFA1 through the JNK/c-Jun, API, and ERK pathways.

Another critical protein, lactoferrin, has been shown to recover expression of BPIFA1 after LPS-induced infection and is a safe, established product utilized in the treatment of various human diseases [18]. Lactoferrin is a key innate material that defends humans from respiratory syncytial virus, middle ear infections, and sinusitis, while LPS is an endotoxin present in the outer membrane of Gram-negative bacteria that is strongly immunogenic in animals. Supplementation with lactoferrin has been shown to indirectly recover BPIFA1 attenuated by LPS through downregulation of the MEK/ERK pathway, suggesting a possible therapeutic benefit for patients with lower expression of BPIFA1 caused by chronic bacterial infection. Multiple studies have noted that intranasal steroids could restore BPIFA1 to normal levels by reactivating AP-1, the transcription factor responsible for regulating expression of BPIFA1 [35, 36].

Matrix metalloproteinases (MMPs) are responsible for degradation of extracellular matrix (ECM) proteins in normal cell turnover and are upregulated in inflammatory diseases of oral tissues [37], as well as in dental caries and oral cancer [38]. It is hypothesized that elevated MMPs may inhibit the function of BPIFA1. Therefore, inflammation itself could be the reason for downregulation of BPIFA1. Reducing inflammation of the nasal epithelium is another strategy to protect BPIFA1 from inhibition mediated by infection or injury.

How these studies were executed and their materials and methods are shown in Table 2 [9, 11–13, 15, 17–19, 39]. Furthermore, Table 3 summarizes the working mechanisms utilized by BPIFA1 to protect humans from related pathogens, viral or bacterial, that infect the upper airway. The primary mode of defense induced by BPIFA1 entails neutralization of

Figure 2: Highly specific expression of BPIFA1 in the human upper airway respiratory system. The major expressed tissues of BPIFA1 are located in the tongue, tonsil, nasal polyps, adenoid, and middle ear (as shown in the left panel). Those lowering BPIFA1 expression are affected by infections and correlated diseases of upper airway tracts (as shown in the right panel).
Table 2: Summary of available BPIFA1 studies, methods of analysis utilized, and related upper airway diseases under study.

| Author (year)/[Reference] | Study design | Material | Methods | Correlated upper airway diseases |
|---------------------------|--------------|----------|---------|----------------------------------|
| Casado et al. (2005)/[9]  | Human (in vivo) | Nasal lavage fluids | Proteomics | Upper airway microbial infections and unclean inhaled air |
| Tsou et al. (2015)/[10]   | Human (in vitro) | Septum squamous carcinoma | Western blot, RT-PCR, IHC for expression levels of BPIFA1 and IL-13 | Human chronic rhinosinusitis with nasal polyps |
| Bingle and Gorr (2004)/[11]| Human (in vitro) | Human oral, nasal and respiratory epithelia | Cell line, genomes sequencing, cDNA, cDNA array etc. | Oral, respiratory, GNB infection |
| Yeh et al. (2010)/[12]    | Human (in vitro) | Nasal polyp epithelial cells in air-liquid interface culture | RT-PCR, Western blot | CRSWNP (chronic rhinosinusitis with nasal polyps) |
| Fornander et al. (2013)/[13] | Human (in vivo) | Nasal lavage fluids | Western blot, 2D gel electrophoresis | Upper airway symptoms |
| Fornander et al. (2011)/[14]| Human (in vivo) | Nasopharyngeal aspiration | 2D gel electrophoresis and mass spectrometry | Respiratory syncytial virus infection |
| Ghafouri et al. (2006)/[15]| Human (in vivo) | Nasal lavage fluids | 2D gel electrophoresis, and matrix assisted laser desorption/ionization time-of-flight mass spectrometry | Seasonal allergic rhinitis |
| Tsou et al. (2013)/[16]   | Human (in vivo) | Sinus polyps | Bacterial culture, RT-PCR, IHC | CRSWNP (chronic rhinosinusitis with nasal polyps) |
| Tsou et al. (2014)/[17]   | Human (in vivo) | Sinus polyps | Bacterial culture, RT-PCR, IHC | Sinonasal infections, CRSWNP |
| Tsou et al. (2017)/[18]   | Human (in vitro) | Nasal RPMI-2650 cells | Western blot, indirect immunofluorescence, confocal laser scanning microscopy, and quantitative fluorescence analysis | CRSWNP (chronic rhinosinusitis with nasal polyps) |
| Rye et al. (2012)/[19]    | Human (in vivo) | Genomic DNA was extracted from blood | Single nucleotide polymorphisms | Otitis media |
| Teran et al. (2012)/[20]  | Human (in vivo) | Nasal aspirates | 2D gel electrophoresis and mass spectrometry | Seasonal influenza A virus |

LPS by direct binding or action as a surfactant to increase macrophage or neutrophil recruitment to the infected area of the upper airway. These mechanisms are discussed in the following sections.

3. Upper Airway Infection and Diseases

Upper airway infections cover a wide disease spectrum in human history from flu virus pandemics to outbreaks of various bacterial infections such as tonsillitis, adenoiditis, sinusitis, pharyngitis, and laryngitis. If not properly controlled or treated, these conditions may be life-threatening. Among infections in the head and neck region, tonsillitis, adenoiditis, and chronic sinusitis are often the most difficult to cure, and they incur major medical costs around the world in both adult and pediatric groups [40]. Various antibiotic-resistant conditions make the diseases hard to treat and susceptible to relapse in current practice due to both the increased population of various penicillin-resistant strains [10] and the intractable condition caused by biofilm accumulation [41]. Therefore, curative surgical procedures such as tonsillectomy and adenoidectomy (T/A) [42], middle ear surgery, and sinus surgery are inevitable and are widely used for chronic or recurrent upper respiratory tract infection (URTI) in child and adult chronic upper airway infection-related diseases. Avoidable surgical treatment options are for patients who have failed to respond to medication, and they are strongly correlated with tissue biofilm formation that subsequently elicits lower BPIFA1 production [16, 17]. Some upper airway infectious diseases such as chronic rhinosinusitis and middle ear infection lead to biofilm formation and lower BPIFA1 expression and require avoidable surgeries. These pathologies are summarized below.

3.1. Middle Ear Infection. Current evidence of the direct relationship between middle ear infection and BPIFA1 is lacking. Middle ear effusion, or otitis media, has been shown to exhibit BPIFA1 gene expression [19, 43]. The indirect relationship of otitis media and BPIFA1 may be related to poor eustachian tube function and BPIFA1 expression. Patients with decreased BPIFA1 expression were also noted to be smokers and to present with allergic rhinitis, conditions...
**Table 3: Summary of mechanisms, correlated pathogens, and findings from studies of BPIFA1 and related upper airway diseases.**

| Author (year)/[Reference] | Mechanism | Pathogen | Findings |
|---------------------------|-----------|----------|----------|
| Casado et al. (2005)/[9]  | Innate immune response in the nose against microbial infections and unclean inhaled air | Not mentioned | LC-ESI-MS/MS was involved in acquired and innate immune response in the nose against microbial infections and unclean inhaled air, e.g., rhinosinusitis |
| Tsou et al. (2015)/[10]   | IL-13 perturbation of GNB-related bacterial infection and BPIFA1 expression in CRSwNP through JNK/c-Jun pathway | Lipopolysaccharide (LPS) related GNB such as *Haemophilus influenza*, *Pseudomonas aeruginosa*, *Klebsiella pneumonia* | IL-13 attenuated LPS (GNB) bacteria-induced BPIFA1 expression causing compromise of certain GNB bacterial infections |
| Bingle and Gorr (2004)/[11] | LPS neutralization | Not mentioned | PLUNC proteins mediate host defense functions in the oral, nasal and respiratory epithelia |
| Yeh et al. (2010)/[12]    | Inhibition of BPIFA1 production | Not mentioned | IL-13 is harmful to the host innate immune response through the inhibition of BPIFA1 production |
| Fornander et al. (2013)/[13] | BPIFA1 is a target of human neutrophil elastase (HNE) activity | Metal working fluids (biocides, surfactants, anti-oxidants and corrosion inhibitors) | IL-1b was significantly higher in subjects with airway symptoms |
| Fornander et al. (2011)/[14] | Innate immune response | Respiratory syncytial virus | A decrease in BPIFA1 in the upper airways may increase the risk for severe pneumonia |
| Ghafouri et al. (2006)/[15] | NLF levels of the cysteine proteinase inhibitors, cystatin S and VEGP were decreased and failed to inhibit proteinase action in SAR | Pollen | BPIFA1 is significantly decreased in the NLF during nasal inflammation by allergic rhinitis |
| Tsou et al. (2013)/[16]   | Anti-bacteria or surfactant | *Pseudomonas aeruginosa* | Sinusitis with bacterial culture positive for *P. aeruginosa* is associated with lower expression of BPIFA1 and unfavorable sinus surgery outcomes |
| Tsou et al. (2014)/[17]   | Anti-bacteria or surfactant | GPC: *Staphylococcus aureus* GNB: *Pseudomonas aeruginosa*, *Haemophilus influenza*, *Klebsiella pneumonia* | BPIFA1 is a novel predictive outcome biomarker for patients with CRSwNP and bacterial colonization Lower BPIFA1 related to multiple bacterial infections |
| Tsou et al. (2017)/[18]   | Lactoferrin increases BPIFA1 expression to regulate inflammation in RPMI-2650 cells through JNK/cJun pathway | Gram-negative bacteria | Lactoferrin could be a possible treatment strategy for LPS-induced chronic rhinosinusitis |
| Rye et al. (2012)/[19]    | Genome-wide associated study of childhood otitis media susceptibility found that decreased BPIFA1 was correlated with higher otitis media in children | Not mentioned | GWAS was performed to identify the genetic determinants of OM in childhood |
| Teran et al. (2012)/[20]  | Lipocalin-1 can enhance the bactericidal activity of lysozyme and exhibit inherent antimicrobial function | Seasonal influenza A virus | To provide the pathogenesis of respiratory infections caused by seasonal influenza A virus in nasal fluid |
which were shown to increase the risk of developing otitis media with related middle ear diseases. This decrease in BPIFA1 expression in sinus or upper airway mucosa also leads to repeated infection of the upper airway, including middle ear infection and sinusitis [44].

3.2. Sinusitis. Chronic rhinosinusitis comprises a notable portion of upper airway infections and is considered a chronic upper airway infectious disease with diffuse sinus mucosa inflammation. In a case control study, the level of expression of BPIFA1 was depressed in patients with chronic rhinosinusitis, and the protein was considered to have provided a protective function in the sinus mucosa [34]. It was found that sinusitis positive for Pseudomonas aeruginosa bacterial culture is associated with decreased BPIFA1 in the sinus mucosa, which may serve as a diagnostic tool to assess expression of BPIFA1 in patients [16]. Furthermore, BPIFA1 expression was found to be significantly reduced in the mucosal epithelia and submucosal glands in patients with multibacterial colonization, particularly those mediated by Staphylococcus aureus and Pseudomonas aeruginosa [17].

3.3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) were found to have lower levels of BPIFA1 expression, which was associated with bacterial colonization [16]. This evidence indicated that decreased levels of BPIFA1 might facilitate bacterial infection in a host, leading to severe disease manifestations. Repeated sinus surgery is correlated with lower BPIFA1 expression and subsequently elevated pseudomonas infection rates. This pattern of repeated surgeries in the sinuses as well as poor surgical outcomes is often observed in CRSwNP [16]. Patients with CRSwNP had higher secretion of interleukin-13 (IL-13), which appears to play a critical role in downregulating BPIFA1 expression. In nasal epithelial cells, IL-13 attenuates BPIFA1 expression by downregulating the lipopolysaccharide- (LPS-) induced activation of phosphorylated JNK and c-Jun [39].

CRSwNP is a disorder characterized by a higher trend of developing Th2-driven inflammation and tissue eosinophilia that may be induced by microbial infection [45]. IL-13, a cytokine predominantly secreted by Th2, has been found to contribute to airway allergies and to suppress BPIFA1 expression in nasal epithelial cells [12].

3.4. Allergic Rhinitis. The BPIFA1 level was significantly lower in patients with persistent allergic rhinitis (AR) [15, 46]. It was reported that patients with allergic rhinitis had significantly higher chronic rhinosinusitis rates than patients without allergic rhinitis [47]. Patients with lower BPIFA1 expression were found to be more susceptible to sinus infection by certain bacterial infection, which may explain this phenomenon.

4. Mechanisms and Therapeutic Use of BPIFA1

4.1. Possible Mechanisms of Defense Function. Several studies have shown that BPIFA1 possesses antimicrobial activity and exhibits the same surfactant properties as airway secretions, a trait that may inhibit the formation of bacterial biofilm. It has also been reported that BPIFA1 plays an important role in the regulation of airway surface liquid (ASL) volume [48]. Mechanistically, BPIFA1 contributes to the innate immune response by directly binding to LPS and yielding a bactericidal or bacteriostatic effect against various bacterial infections, an anti-biofilm function, and surfactant properties. Furthermore, BPIFA1 has been shown to be secreted from chemoattracted neutrophils or macrophages to support innate mucosal immunity in the lower airway [25, 49]. It was also reported that BPIFA1 protein binding to bacterial lipopolysaccharide inhibited the growth of Pseudomonas aeruginosa [50], Klebsiella pneumonia [26], Mycoplasma pneumonia [27], and the Gram-positive bacteria Staphylococcus aureus [28] by its antimicrobial and surfactant adjusting function.

4.2. Mechanism as Surfactant. The surfactant function of BPIFA1 has been well-characterized in vitro. BPIFA1 contains hydrophobic residues and is a pH-sensitive regulator that can specifically bind to the epithelial Na⁺ channel (ENaC) [48]. This channel has been shown to be critical to the regulation of ASL and absorption of fluids in many epithelia and is frequently the rate-limiting factor. In addition, BPIFA1 has been hypothesized to act as volume sensors to inhibit ENaC and thus fluid reabsorption by preventing its cleavage and activation by serine proteases. This mechanism inhibits ENaC-dependent Na⁺ absorption, resulting in preservation of airway surface liquid volume. A proteomics screen for molecules that bind trypsin-sensitive ENaC channels identified BPIFA1 as a candidate volume sensor, which was supported by subsequent RNA interference (RNAi) knockdown experiments that demonstrated an inability to regulate ENaC-mediated fluid reabsorption in bronchial epithelial cell cultures [51]. Furthermore, the addition of recombinant BPIFA1 to culture restored ASL volume and ENaC regulation to normal values. Cells coexpressing cystic fibrosis transmembrane conductance regulator (CFTR) and ENaC were incubated with rBPIFA1, which inhibited ENaC activity but did not affect CFTR [52]. This illustrates the specificity of ENaC inhibition by BPIFA1 and its subsequent restoration of ASL, demonstrating a key molecular mechanism underlying the increase in mucosal fluid secretion by elevated BPIFA1 in response to pathogen exposure.

4.3. Relation of LPS Interaction. Possible biochemical pathways giving rise to anti-pseudomonas and anti-influenza infection may be mapped by surveying elevated chemokines quantitated in BAL and lower airway cell lines or animal lower airway infection models such as higher levels of CXCL1, CXCL2, and CCL20 [50]. CXCL1 recruits neutrophils to the infection site, while CXCL2 recruits monocytes, macrophages, and granulocytes to combat microbial infection by innate immune response. BPIFA1 was found to have an immunomodulatory function through the toll-like receptor 2 (TLR2) pathway [53], which is responsible for recognition of pathogens and recruitment of innate immune cells such as those delineated above. Further, this same review
illustrated that downregulation of TLR2 in non-transformed human bronchial epithelial cells through shRNA interference reduced BPIFA1 expression, demonstrating a positive correlation between the activation of this pathway and secretion of BPIFA1 in innate immune material. It was shown that, in defending the lower airway against *Mycoplasma pneumonia* infection, BPIFA1 signaled through the TLR2-NF-κB pathway and also through TLR2-induced (MARK)/activating protein 1 (AP-1) in human lung epithelium cells [54]. In a recent survey using a nasal epithelium (RP 2650) model, it was demonstrated that BPIFA1 expression was elevated after LPS-induced inflammation though the MEK/ERK pathway, and BPIFA1 expression was attenuated by IL-13 through the JNK and c-Jun signaling pathway [39] as shown in Figure 3. Lactoferrin was shown to recover the suppressed expression of BPIFA1 through downregulation of the MEK1/2-MAPK signaling pathway by preventing BPIFA1 degradation by LPS. However, whether BPIFA1 exactly could bind with LPS is still questioned till now, since there was also a study which revealed that the LPS is not cognate ligand of BPIFA1 [55]. Besides, we will not just get the concept that BPIFA1 has a similar structure of BPI, which is a major LPS receptor. Actually, there is an allergen called dust mite Der P7 having a similar structure [56]. Therefore, we shall not only just focus on BPI but also check other ligand binding proteins in future studies.

4.4. Immune Effects. Neutrophil function was enhanced in the anti-*Mycoplasma pneumonia* immune response induced by BPIFA1 in chronic lung disease [27]. In the lower airway, knockout BPIFA1 mice were shown to have decreased mucociliary clearance and decreased innate immune function [50]. However, this same region in human patients contains human neutrophilic elastase (HNE), which could potentially degrade BPIFA1 in chronic obstructive pulmonary disease (COPD) patients with acute exacerbation of symptoms by nontypeable *Haemophilus influenzae* infection [57]. The mechanism of anti-influenza A function has yet to be elucidated, but it has been shown that increased amounts of BPIFA1 were quantitated after lung and bronchoalveolar lavage (BAL) administration [58]. The protein has been shown to function as an immunomodulatory material in the lower airway, as demonstrated in chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The expression of human BPIFA1 was altered in nasal lavage fluids (NLFs) after exposure to irritants and was quantitated in an increased proportion in NLFs of smokers, suggesting that it is involved in the airway inflammatory response [59, 60].

4.5. Microbial Defense. BPIFA1 was also shown to confer a resistance to *Klebsiella pneumonia* infection through its ability to adjust mucosa surface tension in contrast to the BPIFA1 knockout mouse model [26] and to decrease *Mycoplasma pneumoniae* levels that subsequently inhibited epithelial IL-8 production induced by *Mycoplasma pneumoniae*-derived lipoproteins. High levels of BPIFA1 have been shown to be expressed in normal human and mouse large airway epithelial cells. Although *Mycoplasma pneumoniae* infection increases BPIFA1, IL-13 still decreases BPIFA1 expression and *Mycoplasma pneumoniae* clearance, suggesting that BPIFA1 serves as a novel host defense protein against *Mycoplasma pneumoniae* [23].

4.6. Different Mechanisms and Functions of BPIFA1 between Upper Airway and Lower Airway Infections. The major pathogens present in the lower airway respiratory tract include *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, and *Mycoplasma pneumoniae*, while the population of infectious pathogens in the upper airway includes *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Klebsiella pneumonia*. 

**Figure 3:** Proposed mechanism of IL-13 inhibition of LPS-induced BPIFA1 expression in nasal polyps and adenoid tissue. The IL-13 inhibits BPIFA1 (SPLUNC1) gene expression through a JNK/c-Jun regulation pathway. Lactoferrin also interacts with BPIFA1 in the nasal polyps and adenoid tissues to avoid LPS-induced inflammation via downregulated MEK1/2-MAPK signaling.
Most of the Gram-negative bacilla (GNB) are correlated with LPS toxin-induced infections. BPIFA1 has been shown to neutralize the aforementioned bacterial species in LPS related interaction reported in the lower and upper airways; however, whether BPIFA1 binds to LPS is still questioned [18, 61].

The surfactant function of BPIFA1 is demonstrated mainly in cystic fibrosis in the lower airway and is not widely reported in the mucosa of the upper airway. Furthermore, LPS-induced BPIFA1 expression in the upper airway is mainly involved in JNK/c-Jun [39] and MEK1/2-MARK pathway signaling [18], while the lower airway is mediated by MARK/AP-1 activation through the TLR2 pathway [54]. The lower airway attracted neutrophils and macrophages that could also secrete BPIFA1 and aid in innate immune protection of pulmonary tissue, a phenomenon that has not been reported in the upper airway.

Patients presenting with nasal allergies and Th2-predominant upper airway allergic rhinitis had higher IL-13 expression correlated with low BPIFA1 expression and high sinusitis infection rate than patients lacking a background with allergic rhinitis. This observation also explained a trend in eosinophilic CRS patients who demonstrated higher IL-13 levels and reduced innate immunity to multiple bacterial, and specifically pseudomonas, infections compared to noneosinophilic CRS patients. This pattern was reported in the lower airway in Mycoplasma pneumonia clearance related to asthma pathobiology [23].

4.7. Materials or Cytokines That Affect BPIFA1 Expression. IL-13 inhibits BPIFA1 expression in upper airway infection. Lactoferrin may recover suppressed BPIFA1 expression by antagonizing LPS and could serve as a future treatment material in nasal spray treatment or sinus irrigation during postoperative care (Table 1).

5. Conclusions

The focus of this article was the secretory protein, BPIFA1, which plays a key role in the regulation of airway surface liquid volume and serves in host defense against bacterial infection. BPIFA1 expression was shown to be significantly reduced in the mucosal epithelia and submucosal glands in patients with multibacterial colonization, particularly those mediated by S. aureus and P. aeruginosa, a trend that may serve as a useful diagnostic marker should methods of BPIFA1 upregulation or supplementation be adapted for therapeutic use. CRSwNP patients requiring repeated sinus surgeries for recurrent or persistent sinusitis also presented much lower BPIFA1 expression than those who did not require repeated sinus surgery. Downregulation of BPIFA1 was shown to produce an immune defect that rendered the host more susceptible to bacterial infection, thus indicating that reduced SPLUNC1 expression might facilitate recurrent Staphylococcus aureus and Pseudomonas aeruginosa infections in patients with CRSwNP. It was demonstrated that IL-13 plays a critical role in the regulation of BPIFA1 expression in patients by downregulating the LPS-induced activation of phosphorylated JNK and c-Jun, followed by attenuation of BPIFA1 expression in these patients.

Lactoferrin was shown to decrease LPS-induced inflammation-related protein MEK1/2 and p42/44 MAPK activation under BPIFA1 recovery. This finding might suggest that a new therapy could be developed that utilizes lactoferrin treatment to lessen inflammation and increase immune response in persistent infection of host airways.

It was noted that patients who underwent surgical procedures of T/A did not decrease chronic or recurrent upper respiratory tract infection and that repeated bacterial infections in the adenoid were shown to be caused by antibiotic resistance. Furthermore, it was demonstrated that biofilm formation played a major role in these ENT infections. In addition, the colonies of S. aureus and P. aeruginosa were associated with respiratory diseases, chronic adenoiditis, and rhinosinusitis. Further insight into the mechanism of biofilm resistance raises a useful future direction in infectious diseases and postoperative treatment.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AR           | Allergic rhinitis |
| ASL          | Airway surface liquid |
| BPIFA1       | Bactericidal/permeability-increasing fold containing family A, member 1 |
| CFTR         | Cystic fibrosis transmembrane conductance regulator |
| COPD         | Chronic obstructive pulmonary disease |
| CRSwNP       | Chronic rhinosinusitis with nasal polyps |
| ECM          | Extracellular matrix |
| ENaC         | Epithelial Na+ channel |
| ENT          | Ear-nose-throat |
| GNB          | Gram-negative bacilla |
| HNE          | Human neutrophil elastase |
| IHC          | Immunohistochemistry |
| LBP          | Lipopolysaccharide-binding protein |
| MMPs         | Matrix metalloproteinases |
| NLFs         | Nasal lavage fluids |
| PSP          | Parotid secretory protein |
| SPLUNC1      | Short palate, lung, and nasal epithelium clone 1 |
| TLR2         | Toll-like receptor 2 |
| URTI         | Upper respiratory tract infection |

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Yung-An Tsou, Min-Che Tung, and Chuan-Mu Chen proposed the conception and design of the article structure. Katherine A. Alexander, Wen-Dien Chang, Hsiao-Ling Chen, and Ming-Hsui Tsai analyzed the data and prepared the figures. Yung-An Tsou drafted the manuscript. Hsiao-Ling Chen and Chuan-Mu Chen edited and revised the manuscript. Yung-An Tsou and Min-Che Tung contributed equally to this work.
**Acknowledgments**

The authors would like to thank Dr. Tsu-Fang Wu for his help with discussion and technical issue. This work was supported by Grant MOST-104-2313-B-005-043-MY3 from the Ministry of Science and Technology of Taiwan (Chuan-Mu Chen) and partially supported by the iEGG and Animal Biotechnology Center from the Feature Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE-107-S-0023-A) in Taiwan (Chuan-Mu Chen) and Grant DMR-107-040 from China Medical University, Taichung, Taiwan (Yung-An Tsou). They would like to express their gratitude.

**References**

[1] W. M. Weston, E. E. LeClair, W. Tryzna et al., “Differential display identification of plunc, a novel gene expressed in embryonic palate, nasal epithelium, and adult lung,” *The Journal of Biological Chemistry*, vol. 274, no. 19, pp. 13698–13703, 1999.

[2] C. D. Bingle and L. Bingle, “Characterisation of the human plunc gene, a gene product with an upper airways and nasopharyngeal restricted expression pattern,” *Biochimica et Biophysica Acta—Gene Structure and Expression*, vol. 1493, no. 3, pp. 363–367, 2000.

[3] E. E. LeClair, L. Nguyen, L. Bingle et al., “Genomic organization of the mouse plunc gene and expression in the developing airways and thymus,” *Biochemical and Biophysical Research Communications*, vol. 284, no. 3, pp. 792–797, 2001.

[4] Y.-P. Di, R. Harper, Y. Zhao, N. Pahlavan, W. Finkbeiner, and R. Wu, “Molecular cloning and characterization of spurt, a human novel gene that is retinoic acid-inducible and encodes a secretory protein specific in upper respiratory tracts,” *The Journal of Biological Chemistry*, vol. 278, no. 2, pp. 1165–1173, 2003.

[5] T. T. Wheeler, B. J. Haigh, J. Y. McCracken, R. J. Wilkins, C. A. Morris, and M. R. Grigor, “The BSP30 salivary proteins from cattle, LUNSX/PLUNC and von Ebner’s minor salivary gland protein are members of the PSP/LBP superfamily of proteins,” *Biochimica et Biophysica Acta—Gene Structure and Expression*, vol. 1579, no. 2-3, pp. 92–100, 2002.

[6] L. Bingle and C. D. Bingle, “Distribution of human PLUNC/BPI fold-containing (BPIF) proteins,” *Biochemical Society Transactions*, vol. 39, no. 4, pp. 1023–1027, 2011.

[7] S. Morosky, N. J. Lennemann, and C. B. Coyne, “BPIFB6 regulates secretory pathway trafficking and enterovirus replication,” *Journal of Virology*, vol. 90, no. 10, pp. 5098–5107, 2016.

[8] C. D. Bingle, L. Bingle, and C. J. Craven, “Distant cousins: Genomic and sequence diversity within the BPI fold-containing (BPIF)/PLUNC protein family,” *Biochemical Society Transactions*, vol. 39, no. 4, pp. 961–965, 2011.

[9] B. Casado, L. K. Pannell, P. Iadarola, and J. N. Baraniuk, “Identification of human nasal mucous proteins using proteomics,” *Proteomics*, vol. 5, no. 11, pp. 2949–2959, 2005.

[10] Y. Tsou, C. Lin, H. Hsu et al., “Association of β-Lactam-Sensitive,” *Surgical Infections*, vol. 16, no. 6, pp. 709–715, 2015.

[11] C. D. Bingle and S. U. Gorur, “Host defense in oral and airway epithelia: chromosome 20 contributes a new protein family,” *The International Journal of Biochemistry & Cell Biology*, vol. 36, no. 11, pp. 2144–2152, 2004.

[12] T.-H. Yeh, S.-Y. Lee, and W.-C. Hsu, “Expression of SPLUNC protein in nasal polyp epithelial cells in air-liquid interface culture treated with IL-15,” *American Journal of Rhinology & Allergy*, vol. 24, no. 1, pp. 17–20, 2010.

[13] L. Fornander, P. Graff, K. Wählén et al., “Airway symptoms and biological markers in nasal lavage fluid in subjects exposed to metalworking fluids,” *PLoS ONE*, vol. 8, no. 12, 2013.

[14] L. Fornander, B. Ghafoori, E. Kihlström et al., “Innate immunity proteins and a new truncated form of SPLUNC1 in nasopharyngeal aspirates from infants with respiratory syncytial virus infection,” *Proteomics - Clinical Applications*, vol. 5, no. 9-10, pp. 513–522, 2011.

[15] B. Ghafoori, K. Irandar, J. Lindbom, C. Tagesson, and M. Lindahl, “Comparative proteomics of nasal fluid in seasonal allergic rhinitis,” *Journal of Proteome Research*, vol. 5, no. 2, pp. 330–338, 2006.

[16] Y.-A. Tsou, C.-M. Chen, T.-C. Lin et al., “Decreased SPLUNC1 expression is associated with Pseudomonas infection in surgically treated chronic rhinosinusitis patients who may require repeated sinus surgery,” *The Laryngoscope*, vol. 123, no. 4, pp. 845–851, 2013.

[17] Y. Tsou, M. Peng, Y. Wu et al., “Decreased PLUNC expression in nasal polyps is associated with multidisciplinary colonization in chronic rhinosinusitis patients,” *European Archives of Oto-Rhino-Laryngology*, vol. 271, no. 2, pp. 299–304, 2014.

[18] Y.-A. Tsou, Y.-T. Hung, T.-F. Wu et al., “Lactoferrin interacts with SPLUNC1 to attenuate lipopolysaccharide-induced inflammation of human nasal epithelial cells via down-regulated MEK1/2-MAPK signaling,” *The International Journal of Biochemistry & Cell Biology*, vol. 95, no. 3, pp. 394–399, 2017.

[19] M. S. Rye, N. M. Warrington, E. S. Scaman et al., “Genome-Wide Association Study to Identify the Genetic Determinants of Otitis Media Susceptibility in Childhood,” *PLoS ONE*, vol. 7, no. 10, p. e48215, 2012.

[20] L. M. Teran, S. Rügeberg, J. Santiago et al., “Immune response to seasonal influenza A virus infection: a proteomic approach,” *Archives of Medical Research*, vol. 43, no. 6, pp. 464–469, 2012.

[21] A. Saferali, M. Obeidat, J.-C. R. Rubé et al., “Polymorphisms associated with expression of bpf1/bpfb1 and lung disease severity in cystic fibrosis,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 53, no. 5, pp. 607–614, 2015.

[22] C. D. Bingle and C. J. Craven, “PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx,” *Human Molecular Genetics*, vol. 11, no. 8, pp. 937–943, 2002.

[23] H. W. Chu, J. Thaikottathil, J. G. Rino et al., “Function and regulation of SPLUNC1 protein in mycoplasma infection and allergic inflammation,” *The Journal of Immunology*, vol. 179, no. 6, pp. 3995–4002, 2007.

[24] L. Lukinskeiene, Y. Liu, S. D. Reynolds et al., “Antimicrobial activity of PLUNC protects against Pseudomonas aeruginosa infection,” *The Journal of Immunology*, vol. 187, no. 1, pp. 382–390, 2011.

[25] S. Sayeed, L. Nistico, C. St Croix, and P. Di, “Multifunctional role of human SPLUNC1 in Pseudomonas aeruginosa infection,” *Infection and Immunity*, vol. 81, no. 1, pp. 285–291, 2013.

[26] Y. Liu, J. A. Bartlett, M. E. Di et al., “SPLUNC1/BPIFA1 contributes to pulmonary host defense against klebsiella pneumoniae respiratory infection,” *The American Journal of Pathology*, vol. 182, no. 5, pp. 1509–1513, 2013.

[27] F. Gally, Y. P. Di, S. K. Smith et al., “SPLUNC1 promotes lung innate defense against mycoplasma pneumoniae infection in mice,” *The American Journal of Pathology*, vol. 178, no. 5, pp. 2159–2167, 2011.
[28] W. G. Walton, S. Ahmad, M. S. Little et al., “Structural Features Essential to the Antimicrobial Functions of Human SPLUNC1,” Biochemistry, vol. 55, no. 21, pp. 2979–2991, 2016.

[29] K. M. Akram, N. A. Moyo, G. H. Leeming et al., “An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection,” Mucosal Immunology, vol. II, no. 1, pp. 71–81, 2018.

[30] K. Budding, E. A. Van De Graaf, T. Hoehnagel, C. E. Hack, and H. G. Otten, “Anti-BPIFA1/SPLUNC1: A new autoantibody prevalent in patients with endstage cystic fibrosis,” Journal of Cystic Fibrosis, vol. 13, no. 3, pp. 281–288, 2014.

[31] A. Mulay, K. M. Akram, and D. Williams, “An in vitro model of murine middle ear epithelium,” Disease Models Mechanisms, vol. 9, no. 11, pp. 1405–1417, 2016.

[32] W. Min-man, S. Hong, X. Zhi-qiang, F. Xue-ping, L. Chang-qi, and L. Dan, “Differential proteomic analysis of nasal polyps, chronic sinusitis, and normal nasal mucosa tissues,” Otolaryngology—Head and Neck Surgery, vol. 141, no. 3, pp. 364–368, 2009.

[33] S. Seshadri, D. C. Lin, M. Rosati et al., “Reduced expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic rhinosinusitis,” Allergy, vol. 67, no. 7, pp. 920–928, 2012.

[34] D. Passali, C. Sarafoleanu, C. Manea et al., “PLUNC Proteins Positivity in Patients with Chronic Rhinosinusitis: A Case-Control Study,” The Scientific World Journal, vol. 2014, Article ID 853583, 5 pages, 2014.

[35] J. N. Baraniuk, G. Wong, M. Ali, M. Sabol, and T. Troost, “Glucocorticoids decrease c-fos expression in human nasal polyps in vivo,” Thorax, vol. 53, no. 7, pp. 577–582, 1998.

[36] R. H. Patil, M. Naveen Kumar, K. M. Kiran Kumar et al., “Dexamethasone inhibits inflammatory response via down regulation of AP-1 transcription factor in human lung epithelial cells,” Gene, vol. 645, pp. 85–94, 2018.

[37] E. A. Solovykh, T. B. Karioqlanova, N. E. Kushlinskii, and O. O. Yanushevich, “Matrix metalloproteinases and inflammatory cytokines in the oral fluid of patients with chronic generalized periodontitis various structural materials restoration of teeth and dentition,” Klinichescheskaya Laboratornaya Diagnostika, no. 10, pp. 55–58, 2013.

[38] A. R. Al-Azri, R. J. Gibson, J. M. Bowen, A. M. Stringer, D. Keefe, and R. M. Logan, “Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis,” Journal of Oral Pathology & Medicine, vol. 44, no. 6, pp. 459–467, 2015.

[39] Y. Tsou, C. Lin, H. Chen et al., “Interleukin-13 Inhibits Lipopolysaccharide-Induced BPIFA1 Expression in Nasal Epithelial Cells,” PLoS ONE, vol. 10, no. 12, p. e0143484, 2015.

[40] J. Subtil, J. C. Rodrigues, L. Reis et al., “Adenoid bacterial colonization in a paediatric population,” European Archives of Oto-Rhino-Laryngology, vol. 274, no. 4, pp. 1933–1938, 2017.

[41] K. Proll, “Clinical Aspects on Antibiotic Resistance: Upper Respiratory Tract Infections,” Microbial Drug Resistance, vol. 1, no. 2, pp. 143–147, 1995.

[42] Y.-A. Tsou, C.-C. Lin, C.-H. Lai et al., “Does Adenotonsillctomy really reduced clinic visits for pediatric upper respiratory tract infections? A national database study in Taiwan,” International Journal of Pediatric Otorhinolaryngology, vol. 77, no. 5, pp. 677–681, 2013.

[43] Y. Hadzhiiev, S. Yordanov, D. Popova, and D. Kakchakova, “BPIFA1 gene expression in the human middle ear mucosa,” The Journal of International Advanced Otolaryngology, vol. 13, no. 3, pp. 340–344, 2017.

[44] G. McGillivary and L. O. Bakalezy, “The multifunctional host defense peptide SPLUNC1 is critical for homeostasis of the mammalian upper airway,” Plos ONE, vol. 5, no. 10, 2010.

[45] J. Hsu and A. T. Peters, “Pathophysiology of chronic rhinosinusitis with nasal polyp,” American Journal of Rhinology & Allergy, vol. 25, no. 5, pp. 285–290, 2011.

[46] K. Irander, M. P. Borres, and B. Ghafouri, “The effects of physical exercise and smoking habits on the expression of SPLUNC1 in nasal lavage fluids from allergic rhinitis subjects,” International Journal of Pediatric Otorhinolaryngology, vol. 78, no. 4, pp. 618–622, 2014.

[47] S. Berrettini, A. Carabelli, S. Sellari-Franceschini et al., “Perennial allergic rhinitis and chronic sinusitis: Correlation with rhinologic risk factors,” Allergy: European Journal of Allergy and Clinical Immunology, vol. 54, no. 3, pp. 242–248, 1999.

[48] A. Garcia-Caballero, J. E. Rasmussen, E. Gaillard et al., “SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 27, pp. 11412–11417, 2009.

[49] J. A. Bartlett, B. J. Hicks, J. M. Schlomann, S. Ramachandran, W. M. Nauseef, and P. B. McCray Jr., “PLUNC is a secreted product of neutrophil granules,” Journal of Leukocyte Biology, vol. 83, no. 5, pp. 1201–1206, 2008.

[50] Y. Liu, M. E. Di, H. W. Chu et al., “Increased susceptibility to pulmonary pseudomonas infection in SPLUNC1 knockout mice,” The Journal of Immunology, vol. 191, no. 8, pp. 4259–4268, 2013.

[51] C. A. Hobbs, M. G. Blanchard, O. Aljievic et al., “Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 305, no. 12, pp. L990–L1001, 2013.

[52] A. L. Garland, W. G. Walton, R. D. Coakley et al., “Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 40, pp. 15973–15978, 2013.

[53] H. W. Chu, F. Gally, J. Thaikootathil et al., “SPLUNC1 regulation in airway epithelial cells: Role of toll-like receptor 2 signaling,” Respiratory Research, vol. 11, article no. 155, 2010.

[54] J. Thaikootathil and H. W. Chu, “MAPK/AP-1 activation mediatesTLR2 agonist-induced SPLUNC1 expression in human lung epithelial cells,” Molecular Immunology, vol. 49, no. 3, pp. 415–422, 2011.

[55] F. Ning, C. Wang, K. Z. Berry et al., “Structural characterization of the pulmonary innate immune protein SPLUNC1 and identification of lipid ligands,” The FASEB Journal, vol. 28, no. 12, pp. 5349–5360, 2014.

[56] G. A. Mueller, L. L. Edwards, J. J. Aloor et al., “The structure of the dust mite allergen Der p 7 reveals similarities to innate immune proteins,” The Journal of Allergy and Clinical Immunology, vol. 125, no. 4, pp. 509–e4, 2010.

[57] D. Jiang, S. E. Wenzel, Q. Wu, R. P. Bowler, C. Schnell, and H. W. Chu, “Human Neutrophil Elastase Degradates SPLUNC1 and Impairs Airway Epithelial Defense against Bacteria,” PLoS ONE, vol. 8, no. 5, 2013.

[58] K. S. LeMessurier, Y. Lin, J. A. McCullers, and A. E. Sama-rasinghe, “Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice,” Antiviral Research, vol. 133, pp. 208–217, 2016.
[59] M. Lindahl, B. Stålbom, and C. Tagesson, “Identification of a new potential airway irritation marker, palate lung nasal epithelial clone protein, in human nasal lavage fluid with two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time of flight,” *Electrophoresis*, vol. 22, no. 9, pp. 1795–1800, 2001.

[60] B. Ghafouri, B. Stålbom, C. Tagesson, and M. Lindahl, “Newly identified proteins in human nasal lavage fluid from non-smokers and smokers using two-dimensional gel electrophoresis and peptide mass fingerprinting,” *Proteomics*, vol. 2, no. 1, pp. 112–120, 2002.

[61] Y. A. Tsou, H. J. Huang, W. W. Lin, and C. Y. Chen, “Investigation of Anti-Infection Mechanism of Lactoferricin and Splunc-1,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 907028, 10 pages, 2014.